Multiple Ascending Doses (MAD) of AZD3199 Given Once Daily as Inhaled Formulation Via Turbuhaler to Healthy Men
NCT ID: NCT00713271
Last Updated: 2014-04-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
27 participants
INTERVENTIONAL
2008-08-31
2008-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assess Safety, Tolerability and PK of AZD3199 in Japanese
NCT00772759
AZD2115 Multiple Ascending Dose Study
NCT01445782
To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of Inhaled AZD8683
NCT01419600
To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594
NCT01636024
AZD9164 Single Ascending Dose Study in Healthy Male Subjects
NCT00847249
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Low dose
AZD3199
Low dose
Dry powder for inhalation, o.d., 1+12 days
2
intermediate dose
AZD3199
intermediate dose
Dry powder for inhalation, o.d., 1+12 days
3
high dose
AZD3199
high dose
Dry powder for inhalation, o.d., 1+12 days
4
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AZD3199
Low dose
Dry powder for inhalation, o.d., 1+12 days
Placebo
AZD3199
intermediate dose
Dry powder for inhalation, o.d., 1+12 days
AZD3199
high dose
Dry powder for inhalation, o.d., 1+12 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Non/ex-smokers, Non/ex-nicotine users
Exclusion Criteria
* Any clinically relevant abnormal findings at screening examinations
* Use of any prescribed or non-prescribed medication
18 Years
45 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gabriella Samuelsson Palmgren
Role: PRINCIPAL_INVESTIGATOR
AZ CPU Lund, Sweden
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Lund, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D0570C00002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.